Document is current

Article History

Received: 6 September 2024

Accepted: 8 January 2025

First Online: 12 February 2025

Declarations

:

: Ethics approval and consent to participate are not applicable to this review article.

: Not applicable.

: Dr. Mary McHenry has received consulting fees and honoraria from Sanofi Genzyme and Medexus, and is on the Board of Directors for CAAIF. Dr. Philippe Bégin has received consulting fees and honoraria from ALK, Astra Zeneca, Sanofi, Bausch Health, Pfizer. He is also a clinical trial investigator with DBV Technologies (Viaskin Patch), Regeneron, Novartis, ALK, and Sanofi. He is on the Board of Directors of the CSACI, AAIQ and CAAIF and medical advisor to Food Allergy Canada. Dr. Edmond Chan has received research support from DBV Technologies; has been a member of advisory boards for Pfizer, Miravo, Medexus, Leo Pharma, Kaleo, DBV, AllerGenis, Sanofi Genzyme, Bausch Health, Avir Pharma, AstraZeneca, ALK, Alladapt; was co-lead of the CSACI oral immunotherapy guidelines; is on the Executive of the CSACI (Canadian Society of Allergy and Clinical Immunology); is on the Executive of the CPS (Canadian Paediatric Society) Allergy Section; and is a member of the healthcare advisory board for Food Allergy Canada. Dr. Meriem Latrous has received consulting fees and honoraria from Sanofi, ALK, Pfizer, Miravo, and Bausch Health. Dr. Harold Kim has received honoraria and/or consulting fees from ALK, AstraZeneca, Bausch Health, CSL Behring, GSK, Miravo, Novartis, Medexus, Pfizer, Sanofi, Shire, Takeda.